TVTX
NASDAQTravere Therapeutics Inc.
SectorHealth CareIndustryBiotechnology: Pharmaceutical Preparations
Price$55.95+1.14 (+2.07%)
01:30 PM07:45 PM
News · 26 weeks118-70%
2025-12-282026-06-21
Mix7590d
- Insider35(47%)
- SEC Filings23(31%)
- Other12(16%)
- Earnings4(5%)
- Analyst1(1%)
Latest news
25 items- INSIDERCHIEF MEDICAL OFFICER Inrig Jula gifted 468 shares, decreasing direct ownership by 0.41% to 112,770 units (SEC Form 4)4 - Travere Therapeutics, Inc. (0001438533) (Issuer)
- SECSEC Form S-8 filed by Travere Therapeutics Inc.S-8 - Travere Therapeutics, Inc. (0001438533) (Filer)
- INSIDERDirector Coughlin Timothy exercised 10,000 shares at a strike of $26.52 and sold $500,747 worth of shares (10,000 units at $50.07) as part of a pre-agreed trading plan (SEC Form 4)4 - Travere Therapeutics, Inc. (0001438533) (Issuer)
- INSIDERDirector Baynes Roy D. exercised 4,500 shares at a strike of $21.38 and sold $225,000 worth of shares (4,500 units at $50.00) as part of a pre-agreed trading plan (SEC Form 4)4 - Travere Therapeutics, Inc. (0001438533) (Issuer)
- SECTravere Therapeutics Inc. filed SEC Form 8-K: Leadership Update8-K - Travere Therapeutics, Inc. (0001438533) (Filer)
- PRTravere Therapeutics Announces Planned Retirement of Chief Research Officer in 2027William Rote, Ph.D., chief research officer plans to retire in early 2027 Jula Inrig, M.D., to be named executive vice president, head of research and development and CMO, expanding her responsibilities to include the Company's research organization Travere Therapeutics, Inc., (NASDAQ:TVTX) today announced that William Rote, Ph.D., the Company's chief research officer, plans to retire from the Company in February 2027 following 10 years of service. Jula Inrig, M.D., currently chief medical officer and a member of the Company's executive leadership team, will expand her responsibilities to include the Company's research organization and be named executive vice president, head of research
- SECSEC Form 144 filed by Travere Therapeutics Inc.144 - Travere Therapeutics, Inc. (0001438533) (Subject)
- PRTravere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)Travere Therapeutics, Inc. (NASDAQ:TVTX) today announced that on June 10, 2026, the Compensation Committee of its Board of Directors granted inducement equity grants to six new employees, consisting of inducement restricted stock units, or RSUs, covering an aggregate of 32,000 shares of its common stock. These inducement RSUs are subject to the terms of Travere's 2018 Equity Incentive Plan ("2018 Plan") but were granted outside of the 2018 Plan and were granted as inducements material to the new employees entering into employment with Travere in accordance with Nasdaq Listing Rule 5635(c)(4). The RSUs vest over four years, with 25% of the shares vesting on each anniversary of the grant da
- PRTravere Therapeutics Presents Long-Term Open-Label Extension Data from the Phase 3 DUPLEX Study at the 63rd European Renal Association (ERA) 2026 CongressPatients in the study who initiated and remained on FILSPARI maintained durable and deepened proteinuria reductions, resulting in further achievement of clinically meaningful low proteinuria thresholds over time Patients who transitioned from active control maximum labeled dose irbesartan to FILSPARI after the double-blind study period demonstrated rapid and sustained reductions in proteinuria FILSPARI was generally well tolerated for up to five years of follow-up in the study Travere Therapeutics, Inc., (NASDAQ:TVTX) today announced long-term results from the ongoing Phase 3 DUPLEX Study open-label extension (OLE) of FILSPARI® (sparsentan) in the treatment of focal segmental glomerul
- SECSEC Form 8-K filed by Travere Therapeutics Inc.8-K - Travere Therapeutics, Inc. (0001438533) (Filer)
- PRTravere Therapeutics Enters Into Exclusive Licensing Agreement with Everest Medicines for Civorebrutinib a Potential Best-in-Class BTK Inhibitor for Rare Kidney DiseasesCivorebrutinib is an investigational oral, covalent reversible BTK inhibitor designed to provide differentiated efficacy, safety and convenience in immune-mediated kidney diseases Civorebrutinib adds pipeline-in-a-product potential across multiple rare kidney diseases, expanding and diversifying Travere's pipeline Company to host conference call June 2, 2026 at 8:30 a.m. ET Travere Therapeutics, Inc., (NASDAQ:TVTX) today announced that it has entered into an exclusive licensing and collaboration agreement with Everest Medicines for the development and commercialization of civorebrutinib (also known as EVER001), a potential best-in-class oral, covalent reversible Bruton's tyrosine kina
- PRTravere Therapeutics Receives Notice of Allowance from the U.S. Patent and Trademark Office for U.S. Patent Application Directed to Certain Methods of Using FILSPARI® (sparsentan) in IgA NephropathyTravere Therapeutics, Inc. (NASDAQ:TVTX) today announced that the United States Patent and Trademark Office (USPTO) issued a Notice of Allowance for U.S. Patent Application No. 19/253,088, titled "Biphenyl Sulfonamide Compounds for the Treatment of Kidney Diseases or Disorders," directed to certain methods of using FILSPARI® (sparsentan) in IgA nephropathy. Upon issuance, the patent is expected to provide U.S. patent coverage for certain methods of using sparsentan in IgA nephropathy into October 2037. The allowed application is expected to issue as a U.S. patent following payment of the issue fee and standard USPTO post-allowance processing. Travere expects to submit the issued patent fo
- INSIDERDirector Williams Brinkley Ruth was granted 4,000 shares, increasing direct ownership by 16% to 29,750 units (SEC Form 4)4 - Travere Therapeutics, Inc. (0001438533) (Issuer)
- INSIDERDirector Meckler Jeffrey A was granted 4,000 shares, increasing direct ownership by 5% to 91,500 units (SEC Form 4)4 - Travere Therapeutics, Inc. (0001438533) (Issuer)
- INSIDERDirector Orwin John A was granted 4,000 shares, increasing direct ownership by 11% to 39,375 units (SEC Form 4)4 - Travere Therapeutics, Inc. (0001438533) (Issuer)
- INSIDERDirector Poole Sandra was granted 4,000 shares, increasing direct ownership by 13% to 34,000 units (SEC Form 4)4 - Travere Therapeutics, Inc. (0001438533) (Issuer)
- INSIDERDirector Squarer Ron was granted 4,000 shares, increasing direct ownership by 11% to 39,375 units (SEC Form 4)4 - Travere Therapeutics, Inc. (0001438533) (Issuer)
- INSIDERDirector Baynes Roy D. was granted 4,000 shares, increasing direct ownership by 11% to 41,500 units (SEC Form 4)4 - Travere Therapeutics, Inc. (0001438533) (Issuer)
- INSIDERDirector Lyons Gary A was granted 4,000 shares, increasing direct ownership by 7% to 61,500 units (SEC Form 4)4 - Travere Therapeutics, Inc. (0001438533) (Issuer)
- INSIDERDirector Bruhn Suzanne Louise was granted 4,000 shares, increasing direct ownership by 14% to 32,750 units (SEC Form 4)4 - Travere Therapeutics, Inc. (0001438533) (Issuer)
- INSIDERDirector Coughlin Timothy was granted 4,000 shares, increasing direct ownership by 8% to 56,250 units (SEC Form 4)4 - Travere Therapeutics, Inc. (0001438533) (Issuer)
- SECTravere Therapeutics Inc. filed SEC Form 8-K: Leadership Update, Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits8-K - Travere Therapeutics, Inc. (0001438533) (Filer)
- INSIDERDirector Coughlin Timothy sold $141,342 worth of shares (3,250 units at $43.49) as part of a pre-agreed trading plan, decreasing direct ownership by 6% to 52,250 units (SEC Form 4)4 - Travere Therapeutics, Inc. (0001438533) (Issuer)
- SECSEC Form 144 filed by Travere Therapeutics Inc.144 - Travere Therapeutics, Inc. (0001438533) (Subject)
- PRTravere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)Travere Therapeutics, Inc. (NASDAQ:TVTX) today announced that on May 10, 2026, the Compensation Committee of its Board of Directors granted inducement equity grants covering an aggregate of 48,800 shares of its common stock to four new employees, consisting of inducement stock options to purchase an aggregate of 18,000 shares of common stock and inducement restricted stock units, or RSUs, covering an aggregate of 30,800 shares of its common stock. These inducement stock options and inducement RSUs are subject to the terms of Travere's 2018 Equity Incentive Plan ("2018 Plan") but were granted outside of the 2018 Plan and were granted as inducements material to the new employees entering into
TVTX FAQ
6 questionsWhat does Travere Therapeutics Inc. do?
Travere Therapeutics, Inc., a biopharmaceutical company, focuses on the identification, development, and commercialization of therapies for the treatment of rare diseases. Its marketed products include Chenodal, a synthetic oral form of chenodeoxycholic acid for the treatment of radiolucent stones in well-opacifying gallbladders; Cholbam, a cholic acid capsule to treat pediatric and adult patients with bile acid synthesis disorders due to single enzyme defects, as well as for adjunctive treatment of patients with peroxisomal disorders; and Thiola and Thiola EC, a tiopronin tablet for the...Where does TVTX stock trade?
Travere Therapeutics Inc. (TVTX) is listed on NASDAQ.What sector and industry is TVTX in?
Travere Therapeutics Inc. operates in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry.What are analysts saying about TVTX?
Travere Therapeutics Inc. has had 8 recent analyst actions on file. The most recent action was from Piper Sandler: Overweight with a $4900.00 price target on 2026-04-14. Recent price targets range from $2500.00 to $4900.00.What companies are similar to TVTX?
Notable peers in the same industry include MIRM (Mirum Pharmaceuticals Inc.), KDNY (Chinook Therapeutics Inc.), CALT (Calliditas Therapeutics AB), APLT (Applied Therapeutics Inc.). Compare TVTX side-by-side with any of them on Quantisnow.How can I track TVTX on Quantisnow?
Quantisnow aggregates Travere Therapeutics Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow TVTX to receive live email and push alerts on every new disclosure.